Quanterix, a company developing technology designed to enable earlier disease detection, made its market debut on Thursday. Shares of the company surged after pricing at $15 a share, and opening at $16.25 a share. Kevin Hrusovsky, CEO of Quanterix, was with us to discuss how the company plans to revolutionize healthcare. The fourth-leading cause of death is drug side effects, and drugs only work half the time, says Hrusovsky. He believes that if you can personalize the drugs, you have an opportunity to improve the whole pharmaceutical industry. Quanterix is developing technology that will digitize how they see into blood, and help to see disease long before there are symptoms. Rocket science is being deployed into the blood, says Hrusovsky. He says that if you can see biomarkers and incorporate into fitbits, it can really help improve health.

Share:
More In Science
U.S. Virus Death Toll Rises to 11 With California Victim
The U.S. death toll from the coronavirus climbed to 11 on Wednesday with a victim succumbing in California — the nation's first reported fatality outside Washington state — as officials, schools and businesses came under pressure to respond more aggressively to the outbreak.
Stocks Whipsaw After Fed Cuts Rates to Counter Coronavirus Effects
Stocks are whipping up and down after the Federal Reserve swooped into the market with an emergency rate cut in hopes of shielding the economy from the effects of the fast-spreading virus. Tuesday's surprise move gave stocks a strong, brief boost, but it took just 15 minutes for the gains to evaporate.
Virus Spread Prompts Fed to Slash Rates in Surprise Move
Chairman Jerome Powell said at a news conference that the virus “will surely weigh on economic activity both here and abroad for some time.” It was the Fed's first rate cut since last year, when it reduced its key short-term rate three times.
Load More